Info

Nippon Shinyaku, based in Kyoto, Japan, was founded in 1919 and currently employs about 1800 employees. In 2002, Nippon Shinyaku recorded net income of $16 million ($0.23 per share) on revenues of $380 million. In addition to its other pharmaceutical products, Nippon Shinyaku currently markets Cyclocide and Cyclocide N for acute leukemia, malignant lymphoma, and other solid tumors, and Estracyt for prostate cancer.